5.37
-3.24%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Acotec Scientific Holdings
Its shares trade on HKEX under the ticker 6669.HK. It has been listed since 24 August 2021. In the fiscal year to 31 December 2025, it reported revenue of CN¥751.8m and net income of CN¥139.0m. At that date it held total assets of CN¥2.18bn and shareholders' equity of CN¥1.72bn.
Acotec Scientific Holdings Ltd. is a medical device technology platform company, which engages in research and development on providing treatment solutions for vascular diseases. The company is headquartered in Beijing, Beijing. The company went IPO on 2021-08-24. The firm focuses on interventional treatment of vascular diseases, involving Drug-coated Balloons (DCB) and Percutaneous Transluminal Angioplasty Balloon Catheter (PTA) etc. The firm has established a product portfolio for five major therapeutic areas, including vascular surgery, cardiology, nephrology, neurology and andrology. The firm's business covers China, Asia, Europe and other countries and regions.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 24 Aug 2021
- Employees
- 645
- Website
- acotec.cn ↗
Leadership
Pay as last reported
- Ms. Li JingExecutive Chairman of the Board and Chief Executive Officer, since 2017CN¥4.7m
- Dr. Ulrich SpeckChief Technology Officer
- Ms. Zhang HuiVice President of Sales and Marketing
- Ms. Li WeijiaVice President- Clinical and Regulations
- Mr. Li ChenJoint Company Secretary
- Ms. Yi Li ChingJoint Company Secretary
- Mr. Arthur ButcherNon-Executive Director
- Ms. June ChangNon-Executive Director
- Ms. Ni HongIndependent Non-Executive DirectorCN¥66,000
- Ms. Yee Poon KinIndependent Non-Executive DirectorCN¥66,000
- Mr. Silvio SchaffnerNon-Executive Director, since 2017CN¥1.7m
- Dr. Wang YuqiIndependent Non-Executive DirectorCN¥66,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Acotec Scientific Holdings Ltd. employs 645 full-time employees in Beijing, China.
- The company focuses on interventional vascular disease treatments with DCB and PTA products.
- Acotec's product portfolio covers five therapeutic areas including cardiology and neurology.
Weaknesses
- The company's business is limited to vascular disease treatment solutions in China and Asia regions.
- Acotec's IPO was on 24 August 2021, a relatively recent market entry.
- The firm's product range is concentrated on vascular surgery and cardiology segments.
Opportunities
- Expanding into Europe and other global markets presents growth opportunities for Acotec.
- Acotec's focus on vascular disease treatments aligns with rising healthcare demands.
- The company can leverage its DCB and PTA products for broader therapeutic applications.
Threats
- Competition in the vascular disease treatment market may increase with new entrants.
- Regulatory changes in China could impact Acotec's operations and product approvals.
- Economic downturns in Asia might affect Acotec's revenue from key markets.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.